TY - JOUR
T1 - Distinct phenotypic clusters of glioblastoma growth and response kinetics predict survival
AU - Rayfield, Corbin A.
AU - Grady, Fillan
AU - Leon, Gustavo De
AU - Rockne, Russell
AU - Carrasco, Eduardo
AU - Jackson, Pamela
AU - Vora, Mayur
AU - Johnston, Sandra K.
AU - Hawkins-Daarud, Andrea
AU - Clark-Swanson, Kamala R.
AU - Whitmire, Scott
AU - Gamez, Mauricio E.
AU - Porter, Alyx
AU - Hu, Leland
AU - Gonzalez-Cuyar, Luis
AU - Bendok, Bernard
AU - Vora, Sujay
AU - Swanson, Kristin R.
N1 - Publisher Copyright:
© 2018 American Society of Clinical Oncology.
PY - 2018
Y1 - 2018
N2 - Purpose Despite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on the underlying cause of the differences in patient survivals. Serial imaging assessment of tumor growth allows quantification of tumor growth kinetics (TGK) measured in terms of changes in the velocity of radial expansion seen on imaging. Because a systematic study of this entire TGK phenotype-growth before treatment and during each treatment to recurrence -has never been coordinately studied in GBMs, we sought to identify whether patients cluster into discrete groups on the basis of their TGK. Patients and Methods From our multi-institutional database, we identified 48 patients who underwent maximally safe resection followed by radiotherapy with imaging follow-up through the time of recurrence. The patients were then clustered into two groups through a k-means algorithm taking as input only the TGK before and during treatment. Results There was a significant survival difference between the clusters (P = .003). Paradoxically, patients among the long-lived cluster had significantly larger tumors at diagnosis (P = .027) and faster growth before treatment (P = .003) but demonstrated a better response to adjuvant chemotherapy (P = .048). A predictive model was built to identify which cluster patients would likely fall into on the basis of information that would be available to clinicians immediately after radiotherapy (accuracy, 90.3%). Conclusion Dichotomizing the heterogeneity of GBMs into two populations-one faster growing yet more responsive with increased survival and one slower growing yet less responsive with shorter survival-suggests that many patients who receive standard-of-care treatments may get better benefit from select alternative treatments.
AB - Purpose Despite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on the underlying cause of the differences in patient survivals. Serial imaging assessment of tumor growth allows quantification of tumor growth kinetics (TGK) measured in terms of changes in the velocity of radial expansion seen on imaging. Because a systematic study of this entire TGK phenotype-growth before treatment and during each treatment to recurrence -has never been coordinately studied in GBMs, we sought to identify whether patients cluster into discrete groups on the basis of their TGK. Patients and Methods From our multi-institutional database, we identified 48 patients who underwent maximally safe resection followed by radiotherapy with imaging follow-up through the time of recurrence. The patients were then clustered into two groups through a k-means algorithm taking as input only the TGK before and during treatment. Results There was a significant survival difference between the clusters (P = .003). Paradoxically, patients among the long-lived cluster had significantly larger tumors at diagnosis (P = .027) and faster growth before treatment (P = .003) but demonstrated a better response to adjuvant chemotherapy (P = .048). A predictive model was built to identify which cluster patients would likely fall into on the basis of information that would be available to clinicians immediately after radiotherapy (accuracy, 90.3%). Conclusion Dichotomizing the heterogeneity of GBMs into two populations-one faster growing yet more responsive with increased survival and one slower growing yet less responsive with shorter survival-suggests that many patients who receive standard-of-care treatments may get better benefit from select alternative treatments.
UR - http://www.scopus.com/inward/record.url?scp=85046080845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046080845&partnerID=8YFLogxK
U2 - 10.1200/CCI.17.00080
DO - 10.1200/CCI.17.00080
M3 - Article
C2 - 30652553
AN - SCOPUS:85046080845
SN - 2473-4276
VL - 2018
SP - 1
EP - 14
JO - JCO clinical cancer informatics
JF - JCO clinical cancer informatics
IS - 2
ER -